Merck, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Phase 3

Recruiting

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Ibrutinib
Drug: Nemtabrutinib
Drug: Acalabrutinib

First Posted Date: 2023-11-18

Last Posted Date: 2025-05-31

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1200

Registration Number: NCT06136559

Locations: 🇺🇸
Regions Hospital ( Site 0042), Saint Louis Park, Minnesota, United States
🇺🇸
The Center for Cancer and Blood Disorders ( Site 0032), Fort Worth, Texas, United States
🇨🇳
Wuhan Union Hospital ( Site 2015), Wuhan, Hebei, China

and more 171 locations

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Phase 3

Recruiting

Conditions: Prostatic Neoplasms
Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions: Drug: Abiraterone acetate
Drug: Opevesostat
Drug: Dexamethasone
Drug: Prednisone acetate
Drug: Fludrocortisone acetate
Drug: Enzalutamide
Drug: Hydrocortisone

First Posted Date: 2023-11-18

Last Posted Date: 2025-05-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1500

Registration Number: NCT06136650

Locations: 🇭🇰
Queen Mary Hospital ( Site 0602), Hong Kong, Hong Kong
🇮🇪
St. Vincent's University Hospital ( Site 0652), Dublin, Ireland
🇮🇪
Tallaght University Hospital ( Site 0651), Dublin, Ireland

and more 306 locations

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Phase 3

Recruiting

Conditions: Prostate Cancer Metastatic

Interventions: Drug: Opevesostat
Drug: Abiraterone acetate
Drug: Hydrocortisone
Drug: Enzalutamide
Drug: Fludrocortisone acetate
Drug: Prednisone
Drug: Dexamethasone

First Posted Date: 2023-11-18

Last Posted Date: 2025-05-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1200

Registration Number: NCT06136624

Locations: 🇨🇱
Bradford Hill Norte ( Site 0357), Antofagasta, Chile
🇨🇳
Second Affiliated hospital of Anhui Medical University-Urology ( Site 0408), Hefei, Anhui, China
🇯🇵
Kanazawa Medical University Hospital ( Site 0909), Uchinada, Ishikawa, Japan

and more 276 locations

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

Phase 3

Recruiting

Conditions: Endometrial Cancer

Interventions: Biological: Sacituzumab tirumotecan
Drug: Doxorubicin
Drug: Paclitaxel
Drug: Nab-paclitaxel

First Posted Date: 2023-11-15

Last Posted Date: 2025-05-31

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 710

Registration Number: NCT06132958

Locations: 🇨🇳
Jiangxi Maternal and Child Health Hospital-Oncology Department ( Site 1625), Nanchang, Jiangxi, China
🇨🇳
LinYi Cancer Hospital-Gastrology department ( Site 1630), Linyi, Shandong, China
🇨🇳
Obstetrics & Gynecology Hospital of Fudan University ( Site 1617), Shanghai, Shanghai, China

and more 238 locations

A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

Phase 2

Active, not recruiting

Conditions: Non-segmental Vitiligo

Interventions: Biological: MK-6194
Drug: Placebo

First Posted Date: 2023-11-02

Last Posted Date: 2025-04-02

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 169

Registration Number: NCT06113328

Locations: 🇺🇸
The Vitiligo & Pigmentation Institute of Southern California ( Site 0115), Los Angeles, California, United States
🇹🇷
Ankara Bilkent Şehir Hastanesi-Dermatology ( Site 1502), Ankara, Turkey
🇺🇸
Cahaba Dermatology & Skin Health Center ( Site 0127), Birmingham, Alabama, United States

and more 65 locations

A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)

Phase 1

Active, not recruiting

Conditions: Prostatic Neoplasms
Metastatic Castration-Resistant Prostate Cancer

Interventions: Drug: Opevesostat
Drug: Dexamethasone
Drug: Fludrocortisone acetate
Drug: Hydrocortisone

First Posted Date: 2023-10-27

Last Posted Date: 2024-05-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 6

Registration Number: NCT06104449

Locations: 🇯🇵
Yokohama City University Medical Center ( Site 0002), Yokohama, Kanagawa, Japan
🇯🇵
National Cancer Center Hospital East ( Site 0001), Kashiwa, Chiba, Japan
🇯🇵
Toho University Sakura Medical Center ( Site 0003), Sakura, Chiba, Japan

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

Phase 2

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer
Melanoma
Renal Cell Carcinoma

Interventions: Biological: Pembrolizumab (+) Berahyaluronidase alfa
Biological: Pembrolizumab

First Posted Date: 2023-10-25

Last Posted Date: 2025-04-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 147

Registration Number: NCT06099782

Locations: 🇺🇸
Russell Medical ( Site 0160), Alexander City, Alabama, United States
🇺🇸
Alaska Oncology and Hematology ( Site 0121), Anchorage, Alaska, United States
🇺🇸
Highlands Oncology Group-Research Department ( Site 0133), Springdale, Arkansas, United States

and more 42 locations

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Phase 3

Recruiting

Conditions: Essential Thrombocythemia

Interventions: Drug: Anagrelide
Drug: Bomedemstat
Drug: Busulfan
Drug: Interferon alfa/pegylated interferon alfa
Drug: Ruxolitinib

First Posted Date: 2023-10-12

Last Posted Date: 2025-05-31

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 300

Registration Number: NCT06079879

Locations: 🇺🇸
Los Angeles Cancer Network ( Site 3491), Glendale, California, United States
🇺🇸
Stanford Cancer Institute ( Site 0107), Stanford, California, United States
🇺🇸
The Lundquist Institute ( Site 3423), Torrance, California, United States

and more 155 locations

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

Phase 3

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Biological: Intismeran autogene
Biological: Pembrolizumab
Other: Placebo

First Posted Date: 2023-10-11

Last Posted Date: 2025-05-31

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 868

Registration Number: NCT06077760

Locations: 🇨🇷
ICIMED ( Site 3301), San Jose, Costa Rica
🇺🇸
Alaska Oncology and Hematology ( Site 0039), Anchorage, Alaska, United States
🇺🇸
YUMA REGIONAL MEDICAL CENTER CANCER CENTER ( Site 0020), Yuma, Arizona, United States

and more 185 locations

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Phase 3

Recruiting

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Biological: Sacituzumab tirumotecan
Drug: Docetaxel
Drug: Pemetrexed

First Posted Date: 2023-10-10

Last Posted Date: 2025-05-31

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 556

Registration Number: NCT06074588

Locations: 🇺🇸
UCLA Hematology/Oncology - Santa Monica ( Site 0023), Los Angeles, California, United States
🇺🇸
Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0001), Jacksonville, Florida, United States
🇺🇸
Mid Florida Hematology and Oncology Center ( Site 0005), Orange City, Florida, United States

and more 182 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy